Getting to 4.2

Shire plc's takeout price of $4.2 billion for ViroPharma Inc. is almost 10x the biotech's annual revenues, far above both the industry norm of 5-7x and a recent specialty comp. But some analysts believe the price is justified by Cinryze's sales potential.